NCT05065957 - Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Tract Cancer | Biotech Hunter

Enrollment

180

Participants

Timeline

Start Date

March 29, 2022

Primary Completion Date

July 31, 2026

Study Completion Date

December 31, 2026

Conditions

Biliary Tract Cancer

Interventions

DRUG

D07001-softgel capsules + Xeloda (or TS-1)

"D07001-softgel capsules: 3 times per week (on Days 1, 3, 5, 8, 10, 12, 15, 17, and 19 of a 21-day cycle, 9 doses per cycle).~Xeloda (or TS-1): twice daily for 14 consecutive days followed by 7 days rest (1 treatment cycle)"

DRUG

mFOLFOX

intravenous infusion on Day 1 for 14-day cycle

Trial Locations (5)

404

RECRUITING

China Medical University Hospital, Taichung

807

RECRUITING

Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City

Unknown

RECRUITING

National Taiwan University Cancer Center, Taipei

RECRUITING

National Taiwan University Hospotal, Taipei

RECRUITING

Taipei Veterans General Hospital, Taipei